Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · IEX Real-Time Price · USD
11.21
-0.79 (-6.58%)
At close: May 17, 2024, 4:00 PM
10.82
-0.39 (-3.48%)
After-hours: May 17, 2024, 4:26 PM EDT
Cidara Therapeutics Stock Forecast
CDTX's stock price has decreased by -58.48% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cidara Therapeutics stock have an average target of 61.67, with a low estimate of 25 and a high estimate of 120. The average target predicts an increase of 450.13% from the current stock price of 11.21.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CDTX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +123.02% | May 16, 2024 |
| WBB Securities | WBB Securities | Strong Buy Maintains $40 | Strong Buy | Maintains | $40 | +256.82% | Apr 25, 2024 |
| Needham | Needham | Strong Buy Maintains $3 → $25 | Strong Buy | Maintains | $3 → $25 | +123.02% | Apr 25, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 25, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 23, 2024 |
Financial Forecast
Revenue This Year
21.49M
from 63.91M
Decreased by -66.37%
Revenue Next Year
46.98M
from 21.49M
Increased by 118.58%
EPS This Year
-0.59
from -5.20
EPS Next Year
-0.13
from -0.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.0M | 112.5M | 139.2M | 256.8M | 193.0M |
| Avg | 21.5M | 47.0M | 62.4M | 93.9M | 114.0M |
| Low | 5.7M | 9.1M | 14.4M | n/a | 39.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -51.5% | 423.6% | 196.2% | 311.4% | 105.6% |
| Avg | -66.4% | 118.6% | 32.9% | 50.4% | 21.5% |
| Low | -91.1% | -57.6% | -69.3% | - | -58.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.40 | 0.66 | 0.99 | 42.34 | 23.10 |
| Avg | -0.59 | -0.13 | 0.05 | 3.49 | 10.83 |
| Low | -0.69 | -0.61 | -0.55 | -28.22 | -0.74 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 77,772.2% | 562.2% |
| Avg | - | - | - | 6,316.5% | 210.5% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.